Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959049 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,474
- Enrollment target
NCT00959049 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 1,474 participants.
The verdict
NCT00959049, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,474 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.
Interventions
- BIOLOGICAL CSL's Influenza Virus Vaccine (Afluria)
- BIOLOGICAL Influenza Virus Vaccine (Fluzone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,474 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00959049
The ClinicalTrials.gov registry entry for NCT00959049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CSL's Influenza Virus Vaccine (Afluria) is the first listed.
NCT00959049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00959049 about?
NCT00959049 is a clinical study titled "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population". The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.
What is the current status of trial NCT00959049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,474 participants. The study started on 2009-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00959049?
The interventions under investigation include: CSL's Influenza Virus Vaccine (Afluria) (BIOLOGICAL), Influenza Virus Vaccine (Fluzone) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00959049?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.